Shares in Collagen Solutions (LON:COS) rose this week after the U.K.-based company touted positive data from an eight-year study of 15 patients who received ChondroMimetic implants to repair cartilage defects in their knees.
The company plans to apply for CE Mark clearance in the European Union for its ChrondroMimetic implant based on the results from this long-term study.
Using 3D MRI analyses, researchers found that cartilage regeneration in the defects treated with Collagen Solutions’ device had reached a structural quality that was almost identical to native cartilage. The team also saw that after eight years, patients reported improvements in their pain levels, as well as function and activity levels.
Collagen Solutions also touted that outcomes following the ChondroMimetic procedure were as good, if not better, than those reported in the literature for more expensive, two-step cartilage repair devices.
“Based on our first-hand clinical experience with ChondroMimetic and these new results confirming the sustainability of both cartilage regeneration and the improvement in patient outcomes, it is my firm belief that this scaffold has an important place in the treatment of focal chondral lesions as an alternative to microfracture,” principal investigator Dr. Laszlo Hangody said in prepared remarks.